# Original Article A simple score for predicting renal artery stenosis in patients with ischemic heart disease

Qin Ma<sup>1</sup>, Bin Zheng<sup>1</sup>, Kang Meng<sup>1</sup>, Qiang Yong<sup>2</sup>, Yihua He<sup>2</sup>, Jian Wang<sup>1</sup>, Shiying Li<sup>1</sup>, Donghui Zhao<sup>1</sup>, Zhenye Xu<sup>1</sup>, Peng Hao<sup>1</sup>, Hua Chen<sup>1</sup>, Kun Fu<sup>1</sup>, Ruixi Liu<sup>3</sup>, Shujuan Cheng<sup>1</sup>, Jinghua Liu<sup>1</sup>

<sup>1</sup>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China; <sup>2</sup>Department of Ultrasound, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China; <sup>3</sup>Capital Medical University, Beijing, China

Received December 16, 2014; Accepted February 10, 2015; Epub March 15, 2015; Published March 30, 2015

**Abstract:** Background: Previous risk score is not simple for predicting existence of atherosclerotic renal artery stenosis (ARAS). Our study aims to develop a simple score to predict ARAS in eastern people with ischemic heart disease. Methods: There were two data sources involved in this study. From the data source of patients with acute myocardial infarction, we developed a clinical score for predicting existence of ARAS. After this, we validated this clinical score in data source of patients with ischemic heart failure. Results: By multivariable logistic regression analysis, only age, hypertension, stroke or intermittent claudication, serum creatinine were involved in this model. Receiver operating characteristic curve was plotted. In the first data source, area under curve is 0.808 to predict ARAS, and 0.762 for bilateral ARAS. In the second data source, area under curve is 0.721 to predict ARAS, and 0.827 for ARAS. Cutoff value of 35.0 yields a sensitivity of 82.4% and a specificity of 51.0% for ARAS, a sensitivity of 78.9% and a specificity of 47.1% for bilateral ARAS. In the second data source, this cutoff value yields a sensitivity of 85.0% and a specificity of 30.5% for ARAS, a sensitivity of 85.7% and a specificity of 17.5% for bilateral ARAS. Conclusions: We have developed a simple score for eastern people to predicting existence of ARAS with acceptable sensitivity and specificity in patients with ischemic heart disease. This score is still needed to be validated in general population or patients with no coronary heart disease.

Keywords: Renal artery obstruction, heart failure, systolic, coronary artery disease, myocardial infarction

#### Introduction

Atherosclerotic renal artery stenosis (ARAS) is defined as atherosclerotic narrowing of the renal artery lumen, which usually involves the ostium and proximal third of the main renal artery and the perirenal aorta [1]. Atherosclerosis accounts for approximately 90% of renal artery stenosis cases [2]. As for patients with ARAS, experts are concerned about the risk for deterioration of kidney function as well as for worsening cardiovascular morbidity and mortality [1, 2]. Reported prevalence of renal artery stenosis is different in different study populations [3]. In patients with clinical characteristics suggestive of renovascular hypertension, pooled renal artery stenosis prevalence is about 14.1% [3]. In patients with end-stage renal failure, pooled renal artery stenosis prevalence is about 40.8% [3]. In patients with confirmed coronary heart disease, renal artery stenosis prevalence is about 10.9%-14.8% [4, 5].

Although randomized trials such as ASTRAL and CORAL did not demonstrate benefits of angioplasty for ARAS, angioplasty for ARAS was believed to be beneficial in some population with ARAS [6-8]. In addition, ARAS was believed to be associated with deterioration of renal function in patients taking ACEI/ARB [9]. ACEI/ ARB is indicated in patients with myocardial infarction or heart failure [10-12].

Although screening for ARAS can be accomplished by noninvasive or invasive methods, such as duplex ultrasound, computed tomography angiography, magnetic resonance angiography, and invasive angiography, it is still necessary to develop a score to perform preliminary assessment of possible existence of ARAS. Previous established predicting algorithms has enrolled so many predictors or included invasive procedure [13-15]. So, we think it is necessary to develop a more simple approach. In this study, we developed a score to predict the existence of ARAS in patients with myocardial infarction, and testified its efficacy in patients with ischemic heart failure.

## Methods

## Data source

There were two data sources involved in this study. The first data source is acute myocardial infarction patients with renal arteriography, which has been published elsewhere [16]. From this data source, we developed a score for predicting existence of ARAS. After this, we validated this system in the second data source, i.e. RASHEF database. RASHEF database was founded to investigate Renal Artery Stenosis in *HEart Failure* (RASHEF), including heart failure patients screened for renal artery stenosis. This study was approved by Anzhen Hospital ethics committee.

The first data source has been reported previously [16]. Briefly, Data of patients with acute myocardial infarction was retrieved from the database of hospitalization in Beijing Anzhen Hospital, Capital Medical University. From 2006 to 2010, 9384 patients were admitted as acute myocardial infarction. In the 9384 patients, 257 patients with coronary artery angiography and renal artery angiography performed during hospital stay were included in this study. Patients receiving renal arteriography had the following characteristics: (a) multivessel coronary artery disease; (b) refractory angina; (c) history of accelerated hypertension; (d) resistant hypertension; (e) unexplained renal dysfunction. Written informed consent was obtained before angiography or invasive procedures [16].

The second data source is RASHEF data. Data source of RASHEF patients was retrieved from DHC-PACS/RIS system in Beijing Anzhen Hospital, Capital Medical University. In this DHC-PACS/RIS system from January 2010 to June 2012, renal duplex sonography was performed in 2075 hospitalized patients, including 1925 patients with echocardiography performed during hospital stay. In this 1925 patients, there were 169 patients diagnosed as heart failure. Definition of heart failure in this study was: stage II, III or IV (according to the New York Heart Association classification) heart failure and left ventricular eject fraction < 0.50 by echocardiography. Renal duplex sonography in 2 of the 169 patients was technically inadequate for interpretation. In the remaining 167 patients, 98 patients were diagnosed as ischemic heart failure. Definition of ischemic heart failure in this study was: stage II, III or IV (according to the New York Heart Association classification) heart failure due to coronary artery disease and left ventricular eject fraction < 0.50 by echocardiography.

## Renal angiography

Procedure has been described previously [16, 17]. In this present study, atherosclerotic artery lesion with  $\ge 60\%$  (not  $\ge 70\%$ ) diameter stenosis was termed as ARAS. All the lesions in this data source were diagnosed as atherosclerotic. The reason that we define ARAS as  $\ge 60\%$  whereas not  $\ge 70\%$  diameter stenosis is to develop a score in accordance with renal duplex sonography. Renal duplex sonography can discriminate  $\ge 60\%$  ARAS from < 60% ARAS accurately [18].

## Renal duplex sonography

Renal duplex sonography was performed with Philips iU22G4 ultrasound system or GE Logiq E9 ultrasound system. All the lesions of significant renal artery stenosis in patients with ischemic heart failure were assumed to be atherosclerotic. Patients were classified as with or without significant renal artery stenosis according to the following criteria: 1, a renal-aortic ratio < 3.5 and peak systolic velocity of < 200 cm/s identified patients with < 60% ARAS; 2, a renal-aortic ratio  $\geq$  3.5 or a peak systolic velocity  $\geq$  200 cm/s (or both) identified patients with  $\geq$  60% ARAS; 3, occlusion of renal artery was diagnosed by absence of a flow signal in the renal artery and by a low-amplitude parenchymal signal. This criteria can discriminate  $\geq 60\%$ ARAS from < 60% renal artery stenosis accurately [18].

#### Development of score for ARAS

In this study, we aimed to develop a simple score that can help to identify ARAS in patients with ischemic heart disease. In the first data source, we first performed multivariable logistic regression analysis to identify significant predictors for ARAS. Then, significant variables selected from logistic regression analysis were

	Total (n = 257)	Non-ARAS (n = 206)	ARAS (n = 51)	p value
Male ( <i>n</i> (%))	202 (78.6%)	163 (79.1%)	39 (76.5%)	0.704
Age (years)	59.0 ± 12.2	56.8 ± 12.1	67.8 ± 7.9	< 0.001
Hypertension (n (%))	141 (54.9%)	100 (48.5%)	41 (80.4%)	< 0.001
Stroke or intermittent claudication (n (%))	29 (11.3%)	18 (8.7%)	11 (21.6%)	0.023
Diabetes (n (%))	66 (25.7%)	47 (22.8%)	19 (37.3%)	0.048
Smoking ( <i>n</i> (%))	140 (54.5%)	116 (56.3%)	24 (47.1%)	0.273
Height (cm) (n)	167.9 ± 7.2 (141)	168.2 ± 8.1 (114)	167.8 ± 7.0 (27)	0.780
Weight (kg) ( <i>n</i> )	72.0 ± 10.6 (161)	72.4 ± 11.8 (128)	72.0 ± 10.3 (33)	0.856
Serum creatinine (µmol/L)	88.3 ± 24.7	83.5 ± 17.0	107.6 ± 38.3	< 0.001
Triglyceride (mmol/L)	1.9 ± 1.2	$2.0 \pm 1.3$	1.8 ± 0.8	0.295
Low density lipoprotein cholesterol (mmol/L)	3.3 ± 1.0	3.3 ± 1.1	3.2 ± 0.8	0.388
Anterior wall infarction (n (%))	135 (52.5%)	112 (54.4%)	23 (45.1%)	0.274
Inferior wall infarction (n (%))	92 (35.8%)	71 (34.5%)	21 (41.2%)	0.416
Non-ST elevation myocardial infarction ( $n$ (%))	30 (11.7%)	23 (11.2%)	7 (13.7%)	0.628

Table 1. Baseline characteristics of patient with myocardial infarction (the first data source)

assigned integer score which was proportional to their adjusted odds ratio for ARAS. Score was calculated by sum of weighted variables present. Gold standard of ARAS was defined as narrowing of vessel diameter  $\geq 60\%$  by renal artery angiography. Cutoff value for ARAS was set by sensitivity of 80%.

Validation of this score was assessed in the second data source, i.e. RASHEF patients. Sensitivity and specificity were calculated. Receiver operating characteristic curve was also plotted to present the area under curve.

#### Statistical analysis

Continuous variables are presented as means and standard deviations. Categorical variables are presented as numerals and percentages. Group comparisons were performed with *t* test or Kruskal-Wallis test for continuous variables, chi-square test or Fisher's exact test for categorical variables. Multivariable logistic regression analysis was performed to identify predictors for existence of ARAS. Hosmer-Lemeshow goodness-of-fit test was used to evaluate the goodness of fit of the regression model. A value of P < 0.05 was considered to be statistically significant. Data were processed by SPSS v 13.0 (SPSS Inc., USA).

#### Results

# Patient characteristics

Baseline characteristics of patients with myocardial infarction were summarized in **Table 1**. In this study, criteria for ARAS were defined as  $\geq$  60% (not  $\geq$  70%) diameter stenosis. Data are presented as patients with or without ARAS. There were 257 patients involved for score development. By definition of  $\geq$  70% ARAS, there were 51 (19.8%) patients diagnosed as ARAS, including 34 (13.2%) unilateral ARAS (16 left ARAS, 18 right ARAS) and 17 (6.6%) bilateral ARAS. By definition of  $\geq$  60% ARAS, there were 51 (19.8%) patients diagnosed as ARAS, including 32 (12.5%) unilateral ARAS (16 left ARAS, 16 right ARAS) and 19 (7.4%) bilateral ARAS. All these stenotic lesions were designated as atherosclerotic.

Baseline characteristics of RASHEF patients were summarized in **Table 2**. Data are presented as patients with or without ARAS. There were 98 patients involved for validation of this score. Twenty patients were diagnosed as ARAS, including 13 (13.3%) unilateral ARAS (4 left ARAS, 9 right ARAS) and 7 (7.1%) bilateral ARAS. All these stenotic lesions were assumed as atherosclerotic.

Different from **Tables 1** and **2** indicates that age, hypertension, serum creatinine are not significantly different between patients with ARAS and those without ARAS. This might be attributed to limited sample size in the second data source. In a lager sample, we think that the efficacy of this scoring system might be improved.

#### Development of score

*Multivariate analysis of predictors for ARAS:* As shown in **Table 1**, difference of age, hyperten-

# Simple score for renal artery stenosis

	Total (n = 98)	Non-ARAS ( <i>n</i> = 78)	ARAS ( <i>n</i> = 20)	p value
Male (n (%))	73 (74.5%)	61 (78.2%)	12 (60%)	0.148
Age (years)	62.7 ± 10.7	61.7 ± 10.6	66.7 ± 10.6	0.849
Hypertension (n (%))	73 (74.5%)	55 (70.5%)	18 (90%)	0.090
Stroke or intermittent claudication (n (%))	20 (20.4%)	12 (15.4%)	8 (40%)	0.026
Diabetes (n (%))	39 (39.8%)	28 (35.9%)	11 (55%)	0.133
Smoking ( <i>n</i> (%))	50 (51.0%)	40 (51.3%)	10 (50%)	1.000
Height (cm) (n)	167.4 ± 6.9 (71)	167.4 ± 6.1 (57)	167.6 ± 9.7 (14)	0.888
Weight (kg) (n)	71.2 ± 11.9 (83)	70.6 ± 11.7 (68)	74.1 ± 12.7 (15)	0.301
Serum creatinine (µmol/L)	124.5 ± 102.6	115.3 ± 105.4	160.3 ± 83.8	0.050
Triglyceride (mmol/L)	$1.8 \pm 1.1$	$1.8 \pm 1.1$	$1.7 \pm 1.0$	0.829
Low density lipoprotein cholesterol (mmol/L)	$2.6 \pm 1.0$	$2.5 \pm 0.9$	3.0 ± 1.0	0.051
Anterior wall infarction $(n \ (\%))$	29 (29.6%)	23 (29.5%)	6 (30%)	1.000
Inferior wall infarction $(n \ (\%))$	31 (31.6%)	26 (33.3%)	5 (25%)	0.594
Non-ST elevation myocardial infarction ( $n$ (%))	24 (24.5%)	19 (24.4%)	5 (25%)	1.000
New York Heart Association classification	$2.5 \pm 0.7$	$2.5 \pm 0.7$	$2.4 \pm 0.8$	0.581
left ventricular eject fraction	42.6 ± 6.6	42.8 ± 6.5	41.7 ± 7.3	0.512

Table 2. Baseline characteristics of patient with	ischemic heart failure (the second data source)
---	---

## Table 3. Multivariate analysis of predictors for ARAS

Predictors	HR	95% CI	p value	Assigned score
Transformed age	2.852	1.858-4.379	0.000	3.0
hypertension	3.558	1.449-8.739	0.006	4.0
Stroke or intermittent claudication	3.017	1.130-8.059	0.028	3.0
Diabetes	1.029	0.433-2.444	0.948	0
Serum creatinine (mg/dL)	34.848	7.495-162.021	0.000	30.0

sion, stroke or intermittent claudication, diabetes and serum creatinine between patients with and without ARAS were significant. We assumed that age, hypertension, stroke or intermittent claudication, diabetes, serum creatinine were possible predictors of ARAS. In multivariable logistic analysis, we transformed age into a transformed age. For patients younger than 40 years, age is recorded as zero; for patients older than 40 years, age is transformed into the integral part of (age-40)/10. We transformed serum creatinine (µmol/L) to serum creatinine (mg/dL). Serum creatinine (mg/dL) = serum creatinine (µmol/L)/88.4. By multivariable logistic regression analysis, only transformed age, hypertension, stroke or intermittent claudication, serum creatinine (mg/dL) were significant multivariate predictors for ARAS (Table 3). Goodness of fit for this regression model was evaluated using the Hosmer-Lemeshow goodness-of-fit test (P = 0.074).

Score for existence of *ARAS:* Significant variables selected from logistic regression analysis were assigned integer score proportional to their adjusted hazard ratio (HR) for ARAS (Table 4).

Efficacy of developed score in patients with myocardial infarction (the 1st data source): Receiver operating characteristic curve was plotted to give a cutoff value for diagnosis of possible existence of ARAS (**Figure 1A**). The area under curve is 0.808. We choose cutoff value for ARAS set by the value when the sensitivity is  $\approx$ 80%. Cutoff value of 35.0 yields a sensitivity of 82.4% and a specificity of 51.0%. Cutoff values for different sensitivity are listed in **Table 5**.

As for bilateral ARAS, Cutoff value of 35.0 yields a sensitivity of 78.9% and a specificity of 47.1%. After receiver operating characteristic curve was plotted, area under curve is 0.762 (**Figure 1B**).

Validation of developed score in patients with ischemic heart failure (the 2nd data source): According to cutoff value of 35.0, sensitivity of this score for diagnosis of ARAS is 85.0%, spec-

#### Simple score for renal artery stenosis

Predictors	Score	Predictors	Score
Age (years) < 50	0	Hypertension	4
50-59	3		
60-69	6	Stroke or intermittent claudication	3
70-79	9		
≥80	12	Serum creatinine (mg/dL)	Serum creatinine (µmol/L)/88.4 × 30

Table 4. Score for existence of ARAS



**Figure 1.** Receiver operating characteristic curve was plotted. In the first data source, area under curve is 0.808 for our score to predict ARAS (A), and 0.762 to predict bilateral ARAS (B). In the second data source, area under curve is 0.721 to predict ARAS (C), and 0.827 to predict bilateral ARAS (D).

ificity is 30.5. Score values for different sensitivity are listed in **Table 6**. After receiver operating characteristic curve was plotted, area under curve is 0.721 (Figure 1C).

	1	
Cutoff value	Sensitivity (%)	Specificity (%)
63	10	100
55	20	100
50	30	98
49	40	96
47	50	96
42	60	87
39	70	70
36	80	60
33	90	45
27	100	19

**Table 5.** Sensitivity and specificity by different

 cutoff value in development of our score

As for bilateral ARAS, cutoff value of 35.0 yields a sensitivity of 85.7% and a specificity of 17.5%. After receiver operating characteristic curve was plotted, area under curve is 0.827 (**Figure 1D**).

## Discussion

The major findings of this study were: (1) we developed a score for predicting existence of ARAS in patients with myocardial infarction; (2) this score showed acceptable sensitivity and specificity in its validation in patients with ischemic heart failure.

# Why to develop a score

Risk score can help to screen out possible ARAS. Score must be simple. Angiotensinconverting enzyme inhibitor or angiotensin receptor blocker is recommended in the scenario of acute myocardial infarction and heart failure [10-12]. Although there exists different reports about the safety of ACEI/ARB in patients with ARAS, the prevalence of ARAS still remind us of the possible deterioration of renal dysfunction after initiation of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [9 19]. Inhibition of the renin-angiotensin system leads to a decrease in renal perfusion pressure and efferent arteriolar dilation, which can decrease glomerular filtration rate in patients with renal artery stenosis. Neglecting existence of ARAS may lead to serious sequel, and miss the opportunity for delaying the deterioration of renal insufficiency. Our score takes into medical history and serum creatinine, comes to conclusion very easily. As for invasive procedure indication to screen ARAS, which is

Table 6. Sensitivity and specificity by different
cutoff value in validation of our score

Cutoff value	Sensitivity (%)	Specificity (%)	
115	10	96	
98	20	95	
79	30	94	
72	40	92	
57	50	88	
51	60	78	
41	70	56	
38	80	39	
31	90	16	
21	100	0	

still controversial, our score can help to select proper patient to perform renal arteriography [8].

# Definition of cutoff value

To find out all the possible ARAS with an acceptable specificity is the goal of this clinical score. We define the cut off value for ARAS by a sensitivity of 80%, and get a sensitivity of 82.4% and a specificity of 51.0%. We have select cutoff value by Yoden index. The most Yoden index corresponded to a sensitivity of 50% and a specificity of 90%. This is not compatible with the aim of this study. Neglecting of ARAS is not acceptable.

According to cutoff value 35.0, sensitivity for ARAS is 85.0% and specificity is 30.5% in RASHEF patients. Because it is important to identify ARAS in heart failure, this sensitivity and specificity is acceptable. After receiver operating characteristic curve was plotted, area under curve is 0.721. Decreased glomerular filtration rate in patients with heart failure might explain the decreased specificity. Prerenal azotemia in heart failure might have increased the false positive value.

# Innovation of this clinical score

Previous studies had proposed sophisticated risk scores to estimate possible existence of ARAS. Krijnen et al had proposed a prediction rule for renal artery stenosis that can be used to select patients for renal angiography [13]. Age, sex, atherosclerotic vascular disease, recent onset of hypertension, smoking history, body mass index, presence of an abdominal bruit, serum creatinine concentration, and serum cholesterol level were selected as predictors. This prediction rule was reliable (goodness-of-fit test, P > 0.2), discriminated well between patients with stenosis and those with essential hypertension (area under the receiver-operating characteristic curve, 0.84), and had a sensitivity of 72% and a specificity of 90%. They further validate this prediction rule in a cohort of patients with consecutive patients with drug-resistant hypertension [14]. This prediction rule discriminated reasonably between patients with and without stenosis in the validation sample with an area under the receiver operating characteristic curve of 0.71 [14]. Against its efficacy, so many predictors were involved that this predict rule was not simple for practice.

Cohen et al aimed to identify simple predictors of significant RAS among patients undergoing coronary angiography [15]. Stenosis of more than 75% were considered significant. Independent predictors were older age, higher serum creatinine levels, peripheral vascular disease, number of cardiovascular drugs, hypertension, female sex, and 3-vessel coronary artery disease or previous coronary artery bypass graft. The concordance index of the model was 0.802. Cutoff value of 11 yielded a sensitivity of 76% and a specificity of 71%. This score yielded no better sensitivity and specificity than previous score, but included invasive coronary angiography in risk analysis. Again, this score is not simple.

In our score, if cutoff value was set by sensitivity of 70%, specificity would be 70% in development and 56% in validation (**Tables 5**, **6**), which is similar to Cohen et al's score. In the second data source, area under curve is 0.721 to predict ARAS, and 0.827 to predict bilateral ARAS, which is similar to Krijnen's or Cohen's study. Further, our score system is quite simple, with only four predictors included.

# Limitations

This score for ARAS is sensitive, with an unsatisfactory but acceptable specificity. Secondly, this score was developed from patients with myocardial infarction, validated in patients with ischemic heart failure. In methods, selection of patients for renal arteriography had a bias towards hypertension and renal dysfunction. This bias could have affected the development of this scoring system. It is necessary to validate our score in patients with no coronary heart disease or general population.

# Conclusion

We have developed a score for predicting existence of ARAS in eastern people. In patients with acute myocardial infarction or ischemic heart failure, sensitivity and specificity of this score was acceptable, which needed to be validated in general population or patients with no coronary heart disease.

# Acknowledgements

This work was supported by National Basic Research Program of China (973 program) No. 2015CB554404, Capital Medical University Undergraduate Scientific Research and Innovation Program (XSKY2014113), and Beijing Natural Science Foundation (7142048).

## Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jinghua Liu or Dr. Bin Zheng, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. Tel: +86-10-64412431; Fax: +86-10-64443321; E-mail: liujinghua@vip.sina.com (JHL); zhengbinmedicine@vip.sina.com (BZ)

#### References

- [1] Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, Chew P, Gilbert SJ, Lau J. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med 2006; 145: 901-912.
- [2] Shetty R, Amin MS, Jovin IS. Atherosclerotic renal artery stenosis: current therapy and future developments. Am Heart J 2009; 158: 154-162.
- [3] de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 2009; 27: 1333-1340.
- [4] Wang Y, Ho DS, Chen WH, Wang YQ, Lam WF, Shen ZJ, Lu CZ, Chui M. Prevalence and predictors of renal artery stenosis in Chinese patients with coronary artery disease. Intern Med J 2003; 33: 280-285.

- [5] Fang Y, Shu X, Yang C, Wang X, Wang H, Fu C, Shi W, Zhang Y, Chen Q, Yang L, Zeng C. Stenotic coexistence among coronary, renal and extracrainal arteries in Chinese patients. J Thromb Thrombolysis 2012; 34: 533-540.
- [6] ASTRAL Investigators, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953-1962.
- [7] Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D'Agostino RB Sr, Dworkin LD; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370: 13-22.
- [8] Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA. Antman EM. Smith SC Jr. Adams CD. Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing. Circulation 2006; 113: e463-654.
- [9] Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on re-

nin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 2008; 101: 519-527.

- [10] Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-306.
- [11] Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-81.
- [12] Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
- [13] Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129: 705-711.
- [14] Krijnen P, Steyerberg EW, Postma CT, Flobbe K, de Leeuw PW, Hunink MG. Validation of a prediction rule for renal artery stenosis. J Hypertens 2005; 23: 1583-1588.
- [15] Cohen MG, Pascua JA, Garcia-Ben M, Rojas-Matas CA, Gabay JM, Berrocal DH, Tan WA, Stouffer GA, Montoya M, Fernandez AD, Halac

ME, Grinfeld LR. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 2005; 150: 1204-1211.

- [16] Zheng B, Liu JH, Ma Q, Zhao DH, Wang X, Zheng Z. Association of atherosclerotic renal artery stenosis with major adverse cardiovascular events after acute myocardial infarction. Chin Med J 2014; 127: 618-622.
- [17] Zheng B, Yan HB, Liu RF, Cheng SJ, Wang J, Zhao HJ, Song L. Is it necessary to stent renal artery stenosis patients before cardiopulmonary bypass procedures? Chin Med J 2011; 124: 1453-1457.
- [18] Olin JW, Piedmonte MR, Young JR, DeAnna, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122: 833-838.
- [19] Sofroniadou S, Kassimatis T, Srirajaskanthan R, Reidy J, Goldsmith D. Long-term safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery stenosis. Int Urol Nephrol 2012; 44: 1451-1459.